Article

Alcon receives FDA approval of new multifocal IOL

Alcon Laboratories has received FDA approval for its AcrySof IQ ReSTOR +2.5 D IOL for patients undergoing cataract eye surgery who choose to address near, intermediate, and distance vision needs at the same time.

Alcon Laboratories has received FDA approval for its AcrySof IQ ReSTOR +2.5 D IOL for patients undergoing cataract eye surgery who choose to address near, intermediate, and distance vision needs at the same time.

The lens is the latest addition to Alcon’s portfolio of IOLs for cataract patients and provides an additional option to meet the visual needs of each individual patient, according to the company.


“We are pleased by the FDA’s decision,” said Sabri Markabi, senior vice president, research and development for Alcon. “This technology complements our existing AcrySof IQ ReSTOR +3.0 D IOL in the marketplace, providing more presbyopia-correcting options for ophthalmic surgeons and the patients they serve.” 


The AcrySof IQ ReSTOR +2.5 D IOL is indicated for adult patients with and without presbyopia undergoing cataract surgery who desire near, intermediate, and distance vision with increased spectacle independence.

The Centers for Medicare and Medicaid Services added the AcrySof IQ ReSTOR +2.5 D IOL to the list of CMS recognized presbyopia-correcting IOLs, confirming that AcrySof IQ ReSTOR +2.5 D IOLs will be eligible for reimbursement as both a Medicare-covered service (treatment of cataract) and as a non-covered service (presbyopia correction).

Next: more on the lens

 

The AcrySof IQ ReSTOR +2.5 D IOL will be commercially available in the United States in the near future. The product is already available in the European Union, Australia, Canada, Japan, and countries in Central and South America.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.